Trials / Completed
CompletedNCT00946114
To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
A Local, Multi-Centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For One Hundred Twelve Weeks / Prior To Reimbursement And Availability For Patients In Poland.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 32 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide sildenafil therapy to eligible adult patients with pulmonary arterial hypertension (PAH) and to the patients who completed the A1481142 study for the treatment of PAH in Poland. Only safety and tolerability data will be collected in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sildenafil | tablets, 20mg, TID, 112 weeks at the maximum |
| DRUG | sildenafil | tablets, 20mg x 4 (80mg), TID, approximately 70 weeks |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2009-07-24
- Last updated
- 2021-02-01
- Results posted
- 2010-03-30
Locations
2 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT00946114. Inclusion in this directory is not an endorsement.